相关实验视频

Updated: Apr 16, 2026

Visualization and Quantification of Mesenchymal Cell Adipogenic Differentiation Potential with a Lineage Specific Marker

Visualization and Quantification of Mesenchymal Cell Adipogenic Differentiation Potential with a Lineage Specific Marker

Published on: March 31, 2018

与机器学习相结合的多态学分析确定了FABP4在光滑肌细胞中作为动脉样硬化病原性因素

Yinyu Wang¹, Tingting Shang¹, Rui Cai²

¹Department of Cardiology, Affiliated Hospital of Jiangsu University, Zhenjiang, People's Republic of China.

Journal of inflammation research

|July 31, 2025

概括

研究人员确定了与动脉样硬化相关的特定光滑肌肉细胞 (SMC). 脂肪酸结合蛋白4 (FABP4) 是一个关键标记物,一个潜在的药物, (S) -RP-6306,在研究中有效地准了FABP4.

科学领域:

心血管生物学心血管生物学
分子医学是分子医学.
基因组学就是基因组学.

背景情况:

动脉样硬化,心血管疾病的根本原因,涉及光滑肌肉细胞 (SMCs).
目前针对动脉样硬化的SMC的治疗策略仍然有限.
了解SMC异质性对于开发有效的治疗方法至关重要.

研究的目的:

在动脉样硬化中识别和描述SMC的不同子集.
在SMC中发现新的分子标记物和治疗点.
探索动脉样硬化治疗的潜在候选药物.

主要方法:

单细胞RNA测序和阵列数据分析,以分类SMC.
功能丰富,细胞间通信和差异化潜力分析.
机器学习用于标记物识别和药物标预测.

主要成果:

识别剪刀+ SMCs (动脉样硬化相关) 和剪刀-SMCs.
剪刀+SMC显示出高调节的促炎途径和改变的细胞相互作用.
脂肪酸结合蛋白4 (FABP4) 被确定为一个关键标记物,其中 (S) -RP-6306显示出抑制潜力.

结论:

不同的SMC子集在动脉样硬化中表现出独特的功能和沟通配置文件.
FABP4代表了动脉样硬化的有前途的治疗标.
(S) -RP-6306显示出作为针对动脉样硬化的FABP4向药物的潜力.

关键词:

动脉样硬化动脉样硬化机器学习是机器学习.分子对接的分子对接.顺肌细胞是平滑肌肉细胞.

更多相关视频

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

Isolation of Primary Patient-specific Aortic Smooth Muscle Cells and Semiquantitative Real-time Contraction Measurements In Vitro

Isolation of Primary Patient-specific Aortic Smooth Muscle Cells and Semiquantitative Real-time Contraction Measurements In Vitro

Published on: February 15, 2022

相关概念视频

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...